Developing transformative
medicines for people living
with microvascular disease.
Microvascular focus
Rationale
Tissue Perfusion
Core hemodynamic measures have traditionally focused on blood pressure and cardiovascular output. These measurements imperfectly reflect the tissue perfusion in organs.
Outsized Impact of Demographic Changes
In patients with cardiovascular risk factors such as diabetes, obesity, and even normal aging, structural and functional abnormalities in the microvessels are commonly observed
Technology
Microvascular assessment methods are still limited but rapidly advancing. Genetics and ML/AI enabled technology has potential to improve patient identification and management.
Optimization
Optimizing the microvascular structure and function may substantially improve the CV risk stratification.
Advancing a Pipeline of First-in-class Therapies for Microvascular Dysfunction
CVCO is a clinical-stage pharmaceutical company developing an advanced pipeline of validated, but under-exploited biology, to deliver therapeutic treatment options where none exist. Our experienced leadership team has a track record of building companies that deliver breakthroughs to those who have put their life on pause.
Utilizing Well-understood Molecular Targets to Restore Normal Microvascular Function
Our pipeline consists of clinical-stages programs with oral small molecules. As we advance our broad pipeline of therapies, we place science and data at the core of everything we do.
The CVCO portfolio is the result of a consolidation strategy aimed at addressing microvascular dysfunction. We believe that the clinical evidence that exists today, collected from multiple trials and hundreds of dosed participants, underscores the potential of our programs to be best-in-class treatments for microvascular dysfunction.
The goal of advancing our clinical programs is to help people take control over their health, empowering them with the freedom to change their quality of life and to unpause a life on hold.
Our pipeline is diversified across mechanisms of action
PROGRAM
MECHANISM
INDICATION
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
PROGRAM
Olinciguat* 1x Oral
MECHANISM
sGC stimulator
INDICATION
Microvascular Inflammatory Dysfunction
Coronary microvascular disease
PROGRAM
PROGRAM
MECHANISM
hd Menaquinone-7
INDICATION
Calciphylaxis
*CVCO has also entered into an exclusive license option agreement with Cyclerion for its vascular sGC stimulator, olinciguat.
Led by Pharma Veterans With Deep Industry Expertise and Proven Track Record.
Tony Colasin, MBA
Chief Executive Officer
Over 25 years of biopharma corporate strategy and operational leadership, global corporate development, and partnering deal-maker. Deep patient and payer insight. Portfolio management of the largest PDE discovery and commercialization effort.
Karin Rosen, MD, PhD
Chief Medical Officer
Senior Executive VP & CSO with comprehensive biotech/ pharma industry experience including directing international clinical R&D programs; Leading health authority interactions and launching multiple products.
Mark Currie, PhD
Chief Scientific Officer
Established biopharma R&D leader with over 30 years of demonstrated success in advancing innovative blockbuster treatments to patients. Led the discovery of multiple peptide hormones, primary inventor of Linzess. Recognized leader in GI, CV, Pain, and CNS therapeutic areas.
John M. Rudey, MBA
Executive Chairman
Tony Colasin, MBA
President, CEO & Director
Mark Currie, PhD
CSO & Director
George Johnston, JD
Director
Barry Smith, MD, PhD,
Director.
Perry Halushka, MD, PhD
Distinguished Professor Emeritus, Dean Emeritus, College of Graduate Studies Medical University of South Carolina.
Sagar Nigwekar, MD, MMSc
Assistant Professor of Medicine, Harvard Medical School; Div. of Nephrology, MGH; Co-Director, Kidney Research Center; Medical Director, FKC Chelsea.
C. Michael Gibson, MD
Professor of Medicine, Harvard Medical School; Div. of Cardiology, Served as PI in over 100 clinical trials. Former, FDA Cardiovascular and Renal Drugs Ad. Committee.
Glenn Chertow, MD
Nephrology Chair (former) Stanford University School of Medicine